AtriClip sales pass 34,000

Unit sales of AtriCure's (ATRC -3.2%) AtriClip Left Atrial Appendage Exclusion System have passed 34,000 making it the top-selling device used for eliminating the left atrial appendage (LAA) according to the company.

The LAA is a muscular pouch attached to the heart's left atrium. In patients with atrial fibrillation (AF) and other arrhythmias, blood can pool and form clots in the appendage. As many as 90% of blood clots in AF patients are formed in the LAA. These patients have a 500% greater risk of stroke than the general population.

The FDA approved AtriClip in 2010.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs